Age: 24.0
Sex: F
Vaccine: MNQ
Symptoms: Extra dose administered, Medication error
Clinical narrative: inadvertently received another dose of MENACTRA on 25Jan2022 with no reported adverse event; Initial information received on 25-Jan-2022 regarding an unsolicited valid non-serious case was received from the consumer/non-healthcare professional.  This case involves a 24 years old female patient who inadvertently received another dose of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] on 25jan2022 with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided. The patient had previously received 1 dose of MENACTRA 8 years ago.  On 24-Jan-2022, the patient received suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE total (lot number: U6874AB and Expiration date: 21-Feb-2022) via intramuscular route in the left upper extremity for immunization. On 25-Jan-2022, she also received another dose of the same vaccine at 0.5 ml total (with an unknown batch number; information on batch number was requested) via intramuscular route in the left upper extremity for immunization.  On 25-JAN-2022, the patient developed a non-serious event 'inadvertently received another dose of menactra on 25jan2022 with no reported adverse event' (extra dose administered), 1 day following the administration of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE.  It was reported "caller states the patient received one dose of MENACTRA on 24Jan2022, then they inadvertently received another dose of MENACTRA on 25Jan2022 o Route = route & site - caller states IM left upper extremity was used for both doses. o Dose = 0.25 mL to 2 mL for vaccines or 0.1 mL for TB skin test - 0.5 mL o Strength = standard except for Fluzone HD -- standard o Indications = Immunization or TB skin test - immunizations - Event Information o Treatment - Caller states the patient did not receive any treatment after receiving MENACTRA. o Dose # if series - Caller states the patient had previously received 1 dose of MENACTRA 8 years ago o List concomitant or - no other vaccines- no other vaccines o ER/Dr. visit and date - Caller states the patient did not go to an ER or Dr after receiving MENACTRA. o Lot # U6874AB, Expiration 21Feb2022 o Vaccine presentation/NDC -49281-589-58 o Pregnancy - Caller states the patient was not pregnant at time of administration of MENACTRA. Last menstrual period - Due date - AE symptoms or no AE - Lot # Vaccine presentation/NDC (for example specific flu vaccine) If baby was delivered: delivery date and if baby experienced an adverse event - Inform that they will be receiving a follow up questionnaire - If calling specifically about being added to the pregnancy registry: all pregnancy cases are added to the registry, it is a requirement. No further information provided by the reporter."  Action taken with MENINGOCOCCAL VACCINE (MENACTRA) was not applicable.  At time of reporting, the outcome was Unknown for the event (inadvertently received another dose of menactra on 25jan2022 with no reported adverse event).  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.